Viela Bio launches with $250mm Series A
Viela Bio, a new company developing autoimmune and inflammatory disease therapeutics, raised $250mm in its Series A round. Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital led, and were joined by Temasek and Sirona Capital.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com